Apricus Biosciences jumps on German phase approval for Vitaros


Apricus Biosciences (APRI) gets national phase approval (the company's fifth) in Germany for Vitaros.

The company says the five remaining European phase approvals should be obtainable in Q4 and Q1 2014.

Vitaros' application for marketing approval is approved under the Decentralized Procedure. The Netherlands is the RMS.

APRI has multiple partners for the ED treatment including Takeda (TKPHF.PK), Sandoz, and Abbott (ABT). (PR)

APRI +10% premarket.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs